| Literature DB >> 32435631 |
Yuqi Du1, Chen Wang1, Guodong Cui1, Yiwen Chu2, Qian Jia1, Yi Wang1, Weiming Zhu1,3.
Abstract
R-Pyrisulfoxin C (1), S-pyrisulfoxin D [(+)-2], R-pyrisulfoxin D [(-)-2], pyrisulfoxin E (13), S-pyrisulfoxin F [(+)-14], and R-pyrisulfoxin F [(-)-14], six new caerulomycin derivatives with a 2,2'-bipyridine skeleton, were obtained from the cultures of the endophytic Streptomyces albolongus EA12432 with Aconitum carmichaeli (Ranunculaceae). Additionally, the racemic pyrisulfoxins A [(±)-3] and B [(±)-4] were further purified as optically pure compounds and identified the configurations for the first time. The racemic pyrisulfoxin D [(±)-2] displayed significant cytotoxicity against a series of cancer cell lines with IC50 values ranging from 0.92 to 9.71 μM. Compounds 7, 8, and (±)-3 showed cytotoxicity against the HCT-116, HT-29, BXPC-3, P6C, and MCF-7 cell lines. Notably, compounds 7 and 8 have a strong inhibition both on the proliferation of human colon cancer cells HCT-116 and HT-29 with IC50 values ranging from 0.048 to 0.2 μM (doxorubicin, 0.21 and 0.16 μM), and compound 1 showed a selective inhibition on the proliferation of the gastric carcinoma cell lines, N87, with an IC50 value of 8.09 μM. Optically pure compounds R(-)-14 and S(+)-14 showed weak cytotoxicity against HCT-116 and MCF-7 cell lines with the IC50 values of 14.7 μM and 10.4 μM, respectively. Interestingly, compounds 1 and (±)-2 didn't show cytotoxic activity against two human normal cell lines, HEK-293F and L02, with IC50 values >100 μM.Entities:
Keywords: 2; 2′-bipyridine; Aconitum carmichaeli; Streptomyces albolongus; cytotoxicity; endophyte
Year: 2020 PMID: 32435631 PMCID: PMC7218127 DOI: 10.3389/fchem.2020.00248
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
1H Nuclear Magnetic Resonance (NMR) data of compounds 1, (±)-2, and (±)-2a at 500 MHz.
| 3 | 8.01, s | 7.38, s | 7.15, s | 7.36, s | 8.03, s |
| 4 | – | – | – | – | – |
| 4-OCH3 | 4.05, s | – | – | – | 4.04, s |
| 5 | – | – | – | – | – |
| 5-SOCH3 | 3.06, s | 3.03, s | 3.16, s | 3.01, s | 3.03, s |
| 6 | – | – | – | – | – |
| 7 | 4.96, d (15.0) | 4.71, m | 4.91, m | 4.72, m | 4.65, dd (5.3, 15.8) |
| NHCOCH3 | – | 1.92, s | 2.07, s | 1.92, s | 1.92, s |
| 3′ | 8.46, dd (7.7) | 8.32, d (7.8) | 8.14, d (7.7) | 8.31, d (7.1) | 8.52, d (7.7) |
| 4′ | 7.92, dd (7.7, 7.5) | 7.96, dd (7.8, 7.5) | 7.99, dd (7.7, 7.0) | 7.98, dd (7.1, 6.0) | 8.03, m |
| 5′ | 7.42, dd (7.5, 4.4) | 7.49, dd (7.5, 4.0) | 7.54, dd (7.0, 4.0) | 7.50, brs | 7.53, dd (7.5, 5.0) |
| 6′ | 8.64, d (4.4) | 8.69, d (4.0) | 8.75, d (4.0) | 8.70, brs | 8.73, brs |
| NH | – | 8.49, brs | – | 8.46, brs | 8.33, brs |
Synthetic compound;
Recorded at 600 MHz.
13C NMR data of compounds 1–4, (±)-2a, 13, and (±)-14 at 125 MHz.
| 2 | 160.2, C | Absent | Absent | Absent | 158.3, C | 160.9, C | 161.7, C | absent | 158.0, C |
| 3 | 105.2, CH | 111.3, C | 114.1, C | 111.1, C | 103.6, CH | 105.6, CH | 107.0, CH | 103.4, CH | 103.8, CH |
| 4 | 166.9, C | Absent | Absent | Absent | 164.9, C | 167.8, C | 165.1, C | 168.1, C | 167.9, C |
| 4-OCH3 | 57.1, CH3 | – | – | – | 57.2, CH3 | 57.1, CH3 | 57.4, CH3 | 56.4, CH3 | 56.7, CH3 |
| 5 | 126.0, C | 125.3, C | 127.1, C | Absent | 126.5, C | 127.5, C | 132.2, C | 120.7, C | 118.6, C |
| 5-SO/S-CH3 | 38.8, CH3 | 38.6, CH3 | 39.0, CH3 | 38.9, CH3 | 38.9, CH3 | 38.5, CH3 | 40.4, CH3 | 18.3, CH3 | 18.2, CH3 |
| 6 | 161.0, C | 154.8, C | absent | Absent | 157.4, C | 152.9, C | 133.3, C | absent | 156.6, C |
| 7 | 64.6, CH2 | 41.4, | 37.7, | Absent | 41.5, CH2 | 148.3, CH | 114.9, C | 101.7, CH | 65.7, CH |
| NHCOCH3 | – | 22.5, CH3
| 22.3, CH3
| 22.4, CH3
| 23.4, CH3
| – | – | – | – |
| 7-OCH3 | – | – | – | – | – | – | – | 54.8, CH3 | |
| 2′ | 155.6, C | absent | absent | absent | 154.5, C | 155.6, C | 153.3, C | 155.7, C | 154.9, C |
| 3′ | 123.1, CH | 121.1, CH | 122.3, CH | 121.1, CH | 121.7, CH | 123.2, CH | 122.6, CH | 122.2, CH | 121.9, CH |
| 4′ | 138.7, CH | 137.6, CH | 139.2, CH | 137.7, CH | 138.2, CH | 138.8, CH | 137.8, CH | 137.1, CH | 137.3, CH |
| 5′ | 126.2, CH | 125.0, CH | 126.8, CH | 125.1, CH | 125.5, CH | 126.3, CH | 126.0, CH | 124.2, CH | 124.6, CH |
| 6′ | 150.3, CH | 149.3, CH | 150.7, CH | 149.3, CH | 149.8, CH | 150.3, CH | 149.7, CH | 149.0, CH | 149.1, CH |
Synthetic compound;
Recorded at 150 MHz;
The δ;
Absent in 1D NMR but present in 2D NMR.
1H NMR data of compounds (±)-3, (±)-4, 13, and (±)-14 at 500 MHz.
| 3 | 8.14, s | 8.31, s | 8.01, s | 8.05, s |
| 4 | – | – | – | – |
| 4-OCH3 | 4.15, s | 4.17, s | 4.10, s | 4.12, s |
| 5 | – | – | – | – |
| 5-SO/S-CH3 | 3.15, s | 3.11, s | 2.38, s | 2.44, s |
| 6 | – | – | – | – |
| 7 | 8.44, s | – | 6.09, s | 6.36, s |
| 7-OCH3 | – | – | 3.56, s | 3.56, s |
| NHCOCH3 | – | – | – | – |
| 3′ | 8.49, d (8.0) | 8.52, dd (8.0, 1.2) | 8.56, d (8.0) | 8.33, dd (7.8, 1.5) |
| 4′ | 7.95, dd (8.0, 7.8) | 7.89, ddd (8.0, 7.8, 1.8) | 7.80, dd (8.0, 7.8) | 7.80, ddd (7.8, 7.8, 1.5) |
| 5′ | 7.49, dd (7.8, 5.0) | 7.43, ddd (7.8, 4.6, 1.2) | 7.31, dd (7.8, 4.8) | 7.30, m (overlap) |
| 6′ | 8.67, brs | 8.68, dd (4.6 1.8) | 8.65, d (4.8) | 8.62, dd (4.5, 1.5) |
Recorded at 600 MHz;
The δ.
Figure 2Key 1H-1H COSY and HMBC correlations of 1, (±)-2, and (±)-2a.
Scheme 1The oxidation of 5 and the methylation of (±)-2 into (±)-2a.
Figure 3Experimental and calculated electronic circular dichroism (ECD) spectra of S(+)-2 and R(–)-2 in MeOH.
Figure 5ECD spectra of 1, R(–)-3 and R(–)-4 in MeOH.
Figure 4Experimental and calculated ECD spectra of S(+)-3 and R(–)-3 in MeOH.
Figure 6Key 1H-1H COSY and HMBC correlations of 13 and (±)-14.
Figure 1Structures of compounds 1–3, 13, and 14.
Figure 7Experimental and calculated ECD spectra of S(+)-14 and R(–)-14 in MeOH.
Cytotoxicity of 1 and (±)-2 against cancer and normal cell lines (IC50, μM).
| (±)- | 4.63 | 8.24 | 1.31 | 4.79 | 2.14 | 5.78 | 4.88 | 4.42 | 2.55 |
| Adriamycin | 0.17 | 1.94 | >100 | 0.19 | 0.048 | 0.10 | 0.19 | 17.58 | 0.091 |
| (±)- | 6.90 | 8.05 | 0.92 | 3.67 | 3.13 | 3.18 | 9.71 | 7.46 | 7.38 |
| Adriamycin | 0.13 | 0.097 | 0.18 | 0.12 | 0.39 | 0.21 | 0.16 | 0.12 | 0.49 |
| (±)- | 4.18 | 5.92 | 2.45 | 8.39 | 7.74 | 7.83 | 7.91 | 4.51 | >100 |
| Adriamycin | 0.099 | 0.018 | 0.10 | 0.095 | 0.015 | 0.19 | 0.051 | 0.048 | 0.096 |
The IC.
The IC.
Positive control with an IC.
Cytotoxicity of (±)-3, 7, 8, and 14 against cancer cell lines (IC50, μM).
| (±)- | 0.73 | 0.83 | 3.2 | 1.6 | 13.0 | NT | NT |
| 0.048 | 0.095 | 0.60 | 0.28 | 10.0 | NT | 1.6 | |
| 0.10 | 0.20 | 0.30 | 0.49 | 8.4 | 13.7 | 1.8 | |
| NA | NT | NT | NT | NA | NT | 10.4 | |
| 14.7 | NT | NT | NT | NA | NT | NA | |
| Adriamycin | 0.21 | 0.16 | 0.65 | 0.032 | 0.25 | 0.44 | 0.86 |
NT, not tested,
Positive control,
NA, no activity.